Although these pharmacodynamic assessments do not provide direct tumor-level confirmation, they offer supporting evidence for on-target activity and a cooperative mechanism of action, consistent with the synergy between TOP1 inhibition and PARP trapping. The gene discussed is TOP1; the disease is neoplasm.